Vertex’s Kalydeco Gets EU Approval to Treat CF in Infants
Vertex Pharmaceuticals Inc. VRTX announced that the European Commission has granted marketing authorization to its cystic fibrosis (CF) drug Kalydeco (ivacaftor) for expanded use in infants aged from six to less than 12 months with at least one of specified nine mutations in the CFTR gene. Following this nod, CF patients as young as six months …
News story posted on 2019-12-11T22:56:00.0000000Z
